低级别浆液性卵巢癌的激素受体表达与结局
该研究分析55例晚期低级别浆液性卵巢癌(LGSC)患者的肿瘤组织及细胞系,用Western blot和免疫组化评估ER/PR表达。结果发现96%病例强表达ER、67%表达PR;ER Allred评分越高总生存越好,残留病灶与无进展生存和总生存均相关。雌激素和他莫昔芬未改变LGSC细胞增殖或活力。
要点
- 晚期LGSC中ER强表达占96%、PR表达占67%。
- ER Allred评分较高与更好的总生存显著相关。
- 残留病灶与无进展生存和总生存均显著相关。
核心结论
- 晚期LGSC患者中较高的ER Allred评分与更好的总生存显著相关。
- LGSC肿瘤和细胞系中ER/PR表达随时间变化。
- 雌激素和他莫昔芬未改变LGSC细胞体外增殖或活力。
研究设计与样本
- 研究纳入55例晚期(III/IV期)LGSC病例,肿瘤样本和临床数据来自COEUR组织芯片和OvCaRe组织库。
- ER/PR表达用Western blot和免疫组化评估,采用简单和Allred两种评分系统。
- 用Cox回归分析年龄、疾病残留、ER/PR状态等与PFS和OS相关的因素,并在LGSC细胞系中进行雌二醇和他莫昔芬的增殖与活力实验。
主要发现
- 55例LGSC中位随访56个月(范围1-227)。
- Cox回归显示残留病灶(p < 0.001)与PFS显著相关。
- ER Allred评分(p = 0.005)和残留病灶(p = 0.004)对OS显著。
- 所有LGSC细胞系均不表达PR,肿瘤和细胞系中分别检测到PR和ER表达随时间丢失。
关键数值与推荐
- ER/PR表达采用Western blot和免疫组化评估,免疫组化使用简单和Allred两种评分系统。
- Cox回归分析中残留病灶与PFS相关(p < 0.001),ER Allred评分(p = 0.005)和残留病灶(p = 0.004)与OS相关。
临床怎么用
- 对晚期LGSC患者可评估ER Allred评分,较高评分与更好总生存相关。
- ER/PR表达可能随时间变化,临床解读时需考虑检测时机。
- 体外实验中雌激素和他莫昔芬未改变LGSC细胞增殖或活力,抗雌激素治疗需进一步研究。
局限性
- 需要更好的转化研究模型来阐明LGSC中ER/PR信号传导的分子机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Low-grade serous ovarian carcinomas (LGSC) are frequently ER/PR positive, though the mechanisms by which ER/PR regulate prognosis or anti-estrogen treatment efficacy are poorly understood. We studied ER/PR expression in LGSC tumors and cell lines to evaluate patient outcomes and cellular treatment responses. METHODS: LGSC tumors and patient-derived cell lines were studied from patients with advanced-stage (III/IV) disease. Tumor samples and clinical data were obtained from the Canadian Ovarian Experimental Unified Resource (COEUR-tissue microarray) and the Ovarian Cancer Research (OvCaRe) tissue bank. ER/PR expression was assessed by both Western blot and immunohistochemistry (IHC). Two different IHC scoring systems (simple and Allred) were used. Cox regression was used to identify factors (age, disease residuum, ER/PR status, etc.) associated with progression-free (PFS) and overall survival (OS). Estradiol and tamoxifen proliferation and viability experiments were performed in LGSC cell lines. RESULTS: In 55 LGSC cases studied, median follow-up was 56 months (range 1-227). Fifty-three (96%) cases strongly expressed ER whereas 37 (67%) expressed PR. Cox-regression analysis showed that residuum (p < 0.001) was significantly associated with PFS, whereas both ER Allred score (p = 0.005) and residuum (p = 0.004) were significant for OS. None of the LGSC cell lines expressed PR. Loss of PR and ER expression over time was detected in LGSC tumors and cell lines respectively. Estrogen and tamoxifen treatment did not alter LGSC cell proliferation or viability in-vitro. CONCLUSIONS: In patients with advanced LGSC, higher ER Allred scores were significantly associated with better overall survival. ER/PR expression changed over time in both LGSC tumors and cell lines. Better translational research models are needed to elucidate the molecular mechanisms of ER/PR signalling in LGSC.
引用
- Llaurado Fernandez M, Dawson A, Kim H, et al. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. Gynecol Oncol. 2020. PMID: 31954537. doi:10.1016/j.ygyno.2019.11.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。